Company intelligence / Profile preview

Versameb AG

Ownership: Private
Development stage: Other

Overview

Versameb AG has advanced its lead candidate, VMB‑100, a novel mRNA therapy for stress urinary incontinence, into clinical development with Phase 2a trials scheduled for initiation in 2025. The company leverages its proprietary VERSagile platform to optimize RNA functionality and address unmet medical needs. Preclinical data support the regenerative potential of their approach via modulation of IGF‑1 signaling to restore urethral sphincter function. Additional programs are under development targeting solid tumors and other indications.

Therapeutic areas: Women's HealthOncology
Modalities: mRNA therapeutics
Industry: Biotech

Drug pipeline

1 asset

VMB-100

Discontinued

Partnerships

No major partnerships publicly disclosed as of May 2024; open to selected partners

Beyond the preview

Go deeper on Versameb AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Versameb AG.